Core Viewpoint - Qingdao Hairong Commercial Cold Chain Co., Ltd. announced a change in the use of part of the raised funds for its project due to lower-than-expected market demand and adjustments in project planning [1][2][3][4]. Fund Utilization and Project Details - The "Intelligent Cold Chain Equipment and Commercial Vending Machine Industrialization Project" has a total planned investment of 652.42 million yuan, with 493.74 million yuan intended to be funded by raised capital [1]. - As of June 30, 2025, the project has utilized approximately 264.36 million yuan of the raised funds, leaving a balance of about 269.54 million yuan [2]. - The project has faced delays, with an expected completion date now set for December 31, 2025, due to slower-than-anticipated market penetration in the unmanned retail sector and a decline in the growth rate of the fast-moving consumer goods industry [2][3]. Adjustments in Project Planning - The actual investment in land and equipment has fallen short of the original plan, with land investment at 185.93 million yuan, which is 129.90 million yuan less than planned, and equipment costs at 78.42 million yuan, which is 190.08 million yuan less than planned [3]. - The company has determined that existing production capacity is sufficient to support future domestic business needs, leading to no plans for further large-scale investments in the original project [3]. Reallocation of Funds - The company plans to reallocate over 90 million yuan of the remaining raised funds to a new project in Indonesia, which involves establishing a subsidiary and building a commercial display cabinet manufacturing plant [4]. - This reallocation is necessary due to increased construction area, adjustments in production line layout, and the need for additional production equipment to enhance the production capacity of intelligent vending machines and commercial vending machines [4].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的 任 何 損 失 承 擔 任 何 責 任。 建議變更H股募集資金用途 H股募集資金基本情況 茲提述(i)本公司日期為2015年7月28日 的H股 招 股 說 明 書（「招股書」）, (ii) 本公司日期為2020年3月25日的建議變更H股 募 集 資 金 用 途 公 告（「該公告」） 及(iii)本公司日期為2020年5月15日的本公司2019年 度 股 東 週 年 大 會 通 函， 內 容 有 關（其 中 包 括）本 公 司H股募集資金基本情況及變更H股募集資金 用 途。除 另 有 界 定 者 外，本 公 告 所 用 詞 彙 與 招 股 書 及 該 公 告 所 界 定 者 具 有 相 同 涵 義。 中 國 鐵 路 通 信 信 號 股 份 有 限 公 司 China Railway Signal & Communication Corporation Limited* （在中華人 ...

Core Viewpoint - The company has approved several resolutions during its board meetings, including changes in the use of raised funds and the establishment of a wholly-owned subsidiary in Shenzhen for a research and design center, aimed at enhancing its core competitiveness and optimizing fund utilization [10][33][49]. Group 1: Company Overview - The company is named Hunan Hualian Ceramics Co., Ltd. and is publicly listed with the stock code 001216 [1]. - The company has not experienced any changes in its controlling shareholder or actual controller during the reporting period [5][6]. Group 2: Financial and Operational Decisions - The board approved a resolution to change the use of part of the raised funds amounting to 71.48 million yuan (including interest) from the engineering technology center project to the Shenzhen research and design center project [10][24]. - The total investment for the Shenzhen research and design center project is 130 million yuan, with the company planning to use up to 100 million yuan for purchasing office space [11][26]. Group 3: Related Party Transactions - The company has approved a new annual related party transaction with Hunan Yaran Porcelain Trading Co., Ltd., with an estimated total amount not exceeding 130,000 yuan for 2025 [53][54]. - The related party transactions are conducted based on fair market pricing and do not harm the company's interests [9][63]. Group 4: Upcoming Events - The company plans to hold its fourth extraordinary general meeting of shareholders on September 11, 2025, to discuss various proposals, including the changes in the use of raised funds [66][67].

Summary of Key Points Core Viewpoint The company, Hunan Hualian Ceramics Co., Ltd., is undergoing changes in the use of part of its raised funds for investment projects, aiming to enhance its strategic development and improve the efficiency of fund utilization. Group 1: Fundraising and Project Changes - The company raised a total of RMB 589,997,979.00 from the public offering of 62,966,700 shares, with a net amount of RMB 532,679,111.08 after deducting related expenses [1][2] - The company has made multiple adjustments to its fundraising projects, including changes approved in various shareholder meetings, focusing on optimizing the use of funds for specific projects [3][4] Group 2: New Project Details - The company plans to allocate RMB 71,483,700 (including interest) from the engineering technology center project to the Shenzhen R&D Design Center project [5][6] - The total investment for the Shenzhen R&D Design Center project is RMB 130,000,000, with RMB 71,483,700 proposed to be funded from the raised funds [7][8] Group 3: Strategic Reasons for Changes - The changes are aligned with the company's strategic development needs, aiming to enhance core competitiveness and attract high-level talent by establishing the R&D center in Shenzhen [6][9] - The company emphasizes the importance of optimizing fund allocation to improve the efficiency of fund usage and adapt to market trends [6][10] Group 4: Decision-Making Process - The changes in the use of funds have been reviewed and approved by the company's board of directors, supervisory board, and independent directors, ensuring compliance with relevant laws and regulations [12][13] - The independent directors confirmed that the adjustments are necessary for the company's operational needs and do not harm the interests of shareholders [12][13]

Summary of Key Points Core Viewpoint The report outlines the fundraising activities and the usage of proceeds from the convertible bonds issued by Hangzhou Tiandi Digital Technology Co., Ltd. It highlights the total amount raised, the allocation of funds, and the changes in project funding due to strategic adjustments. Group 1: Fundraising Overview - The company raised a total of RMB 172 million through the issuance of 1,720,000 convertible bonds at a face value of RMB 100 each, with net proceeds amounting to RMB 166.4 million after deducting fees [1][2] - As of June 30, 2025, the net amount of raised funds was RMB 164.297 million, with RMB 6.69963 million utilized for various projects [2][3] Group 2: Fund Usage and Management - The company has allocated RMB 9.47507 million of the unutilized funds and its interest income to a new project, the "Annual Production Line of 230 Million Square Meters of Intelligent Recognition Materials (Phase II)" [3][4] - The company signed tripartite supervision agreements with banks to ensure proper management of the raised funds [2][3] Group 3: Changes in Fund Allocation - The company decided to change the use of the raised funds from the original projects, including "Heat Transfer Coating Equipment and Product Technology Upgrade Project," to the new project due to market conditions affecting the original plans [4][5] - The total investment for the new project is RMB 100.1834 million, with the company providing the funds through loans, while the remaining amount will be covered by the subsidiary's own funds [3][4] Group 4: Financial Management of Idle Funds - The company is authorized to use up to RMB 80 million of idle funds for cash management, investing in safe and liquid financial products [5][10] - As of June 30, 2025, the company had no idle funds temporarily supplementing working capital [5][10] Group 5: Fund Balance and Future Plans - As of June 30, 2025, the remaining balance of the raised funds was RMB 62.669 million, which will be gradually invested in the committed projects [11] - The company has not encountered any issues regarding the use and disclosure of the raised funds, ensuring compliance with relevant regulations [7][8]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 （於中華人民共和國註冊成立之股份有限公司） （股份代號 ： 1065） 建議終止部分募投項目的公告 茲提述天津創業環保集團股份有限公司（「本公司」）日期同為2021年11月22日有 關(1)終止2020年度經調整的非公開發行A股股票事項；(2)建議非公開發行A股； (3)特別授權；及(4)建議採納股東回報規劃的相關公告及海外監管公告，日期為 2021年12月8日的相關通函（「該通函」），日期為2021年12月8日的2021年第四次臨 時股東大會通告及2021年第二次H股類別股東大會通告，日期為2021年12月10日 有關非公開發行A股股票獲得天津市國資委批覆的公告，日期為2021年12月24日 的2021年第四次臨時股東大會、2021年第二次H股類別股東大會及2021年第二次 A股類別股東大會決議公告，日期為2022年1月11日有關非公開發行A股股票申 請獲得中國證監會受理的公告，日期為2022年2月7 ...

Core Viewpoint - The company, Diou Home Group Co., Ltd., is expected to report a significant loss in the first half of 2025, leading to a downgrade in its credit rating by Dongfang Jincheng International Credit Rating Co., Ltd. [1][2] Financial Performance - Diou Home Group anticipates a net loss attributable to shareholders of between 75 million yuan and 95 million yuan for the first half of 2025, which represents an increase in losses compared to the same period last year [1][2]. - The increase in credit impairment losses is attributed to the aging structure of receivables and specific provisions made during the period [2]. - The deferred income tax expense has increased compared to the previous year due to the reversal of impairment provisions related to non-cash asset settlements and asset disposals [2]. Fund Utilization - The company has decided to change the use of funds raised from the issuance of "Diou Convertible Bonds," reallocating 47.65843 million yuan of surplus funds to permanently supplement working capital [3]. - This decision was approved by the company's fourth extraordinary general meeting of 2025 and the first bondholders' meeting for "Diou Convertible Bonds" in 2025 [3].

Summary of Key Points Core Viewpoint The company, Shandong Linuo Pharmaceutical Packaging Co., Ltd., has decided to change the use of part of the raised funds from its convertible bond issuance to better align with its current development needs and strategic planning. Group 1: Fundraising Overview - The company issued 5 million convertible bonds with a total fundraising amount of 500 million RMB, netting 491.44 million RMB after deducting fees [1][2] - The original project for the raised funds was the industrialization of lightweight pharmaceutical molded glass bottles, with a total investment of 641.87 million RMB [2][4] - As of August 10, 2025, 126.05 million RMB of the raised funds had been utilized, leaving an unused amount [2][4] Group 2: Change in Fund Usage - The company plans to reallocate 154 million RMB from the original project to two new projects: acquiring a 30% stake in Chuangyang Co. and the second phase of the high-end pharmaceutical packaging project [2][5] - The new projects include an investment of 84 million RMB for the acquisition and 70 million RMB for the high-end packaging project [2][5] Group 3: Rationale for Change - The original project faced delays due to late delivery of construction facilities and lengthy customer certification processes, leading to a reduced funding requirement [4][5] - The company received a government subsidy of 89.58 million RMB for the original project, further decreasing the need for raised funds [4][5] Group 4: New Investment Projects - The acquisition of a 30% stake in Chuangyang Co. aims to enhance the company's product offerings and market share in pharmaceutical packaging [5][8] - The second phase of the high-end packaging project focuses on RTU (Ready-to-Use) packaging and pre-filled syringes, with a total investment of 383.37 million RMB [9][10] - The project is expected to have a payback period of 6.82 years and an internal rate of return of 16.37% [9] Group 5: Strategic Importance - The new projects align with the growing demand for high-quality pharmaceutical packaging driven by trends in the pharmaceutical industry [10][11] - The company aims to transition from a traditional pharmaceutical glass manufacturer to a diversified high-end packaging solution provider [10][12] - The strategic shift is supported by national policies promoting the development of the pharmaceutical packaging industry [13][14] Group 6: Approval Process - The board of directors and the supervisory board have approved the change in fund usage, ensuring compliance with relevant regulations [16][17] - The independent directors also confirmed that the decision aligns with the company's interests and does not harm shareholder value [17][18]

Core Viewpoint - The company, Shandong Linuo Pharmaceutical Packaging Co., Ltd., is changing the use of part of the raised funds from its convertible bond issuance to better align with its strategic development needs and improve fund utilization efficiency [2][19]. Summary by Sections Fundraising Overview - The company issued 5 million convertible bonds with a net fundraising amount of RMB 491.4447 million, after deducting underwriting fees [2][3]. - As of August 10, 2025, a total of RMB 126.0511 million has been invested from the raised funds, with the remaining amount stored in dedicated bank accounts [3][5]. Change in Fund Usage - The company plans to change the use of RMB 154 million from the "Lightweight Pharmaceutical Glass Bottle (Class I) Industrialization Project" to invest in two new projects: acquiring 30% equity in Suzhou Chuangyang New Materials Technology Co., Ltd. and the second phase of the high-end pharmaceutical packaging project [3][4]. - The new projects include an investment of RMB 84 million for the equity acquisition and RMB 154 million for the high-end packaging project [3][6]. Reasons for Change - The original project faced delays due to late delivery of construction facilities and longer customer certification cycles, leading to a reduced need for the originally planned funds [5][6]. - The company received a government subsidy of RMB 89.58 million, which decreased the funding requirement for the original project [5][6]. New Investment Projects - The acquisition of 30% equity in Suzhou Chuangyang New Materials is aimed at enhancing the company's product offerings and market share in pharmaceutical packaging [6][10]. - The second phase of the high-end pharmaceutical packaging project focuses on the production of Ready-to-Use (RTU) packaging and pre-filled syringes, with a total investment of RMB 383.3725 million, of which RMB 70 million will come from the raised funds [10][11]. Impact of Changes - The changes in fund usage are expected to enhance the company's operational efficiency and long-term benefits without adversely affecting its existing business or financial status [19][20]. - The company will implement strict internal and external supervision of the fund usage to ensure compliance with relevant regulations [20][21].

Core Viewpoint - The report highlights significant growth in revenue and net profit for Kunming Chuanjin Nuo Chemical Co., Ltd. in the first half of 2025, indicating a strong financial performance and strategic investments in new projects [1][4]. Financial Performance - Operating revenue for the reporting period reached approximately CNY 1.74 billion, representing a 27.91% increase compared to the same period last year [1]. - Net profit attributable to shareholders was approximately CNY 177.50 million, marking a substantial increase of 166.51% year-on-year [1]. - The net cash flow from operating activities was approximately CNY 170.95 million, a remarkable increase of 423.23% compared to the previous year [1]. - Basic earnings per share were CNY 0.6457, up 166.49% from CNY 0.2423 in the same period last year [1]. Asset and Equity Position - Total assets at the end of the reporting period were approximately CNY 3.67 billion, reflecting a 1.66% increase from the previous year [3]. - Net assets attributable to shareholders increased to approximately CNY 2.64 billion, a rise of 3.91% year-on-year [3]. Strategic Investments - The company signed a project investment agreement with the Dongchuan District Government to construct a waste disposal project with a total investment of approximately CNY 350 million [4]. - The company approved an investment project in Egypt, which includes the production of various phosphate chemicals with an annual capacity of 800,000 tons of sulfuric acid and other related products [5][6].